IMC-C225 is designed to target and block the Epidermal Growth Factor Receptor - found on the surface of cancer cells in the majority of cases of metastatic colorectal cancer.
IMC-C225 blocks Epidermal Growth Factor Receptor
Developers ImClone Systems, of New York City, USA, said the results of the phase II trial were favorable, showing tumor shrinkage and a slowing of the development of disease in these patients.
Preliminary results show that its main adverse effect is an acne-like rash when given to patients with irinotecan-refractory colorectal cancer, its developers have announced.
IMC-C225 was combined with irinotecan for the open-label phase II trial, conducted by Dr Leonard Saltz, of Memorial Sloan-Kettering Cancer Center, New York.
The acne-like rash was the most common side effect but resolved after treatment. There were infrequent cases of anaphylaxis. The trials showed few signs of the drug aggravating or causing typical chemotherapy side effects.
Dr Harlan Waksal, executive vice president of ImClone Systems said: "This treatment approach of IMC-C225 and irinotecan may represent a promising step toward addressing the void in treatment for the large segment of colorectal carcinoma patients who have progressed through standard therapy.
"We are encouraged by these preliminary findings and are awaiting completion of our final analysis."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com